186 related articles for article (PubMed ID: 25129557)
21. Phase II and gene expression analysis trial of neoadjuvant capecitabine plus irinotecan followed by capecitabine-based chemoradiotherapy for locally advanced rectal cancer: Hoosier Oncology Group GI03-53.
Chiorean EG; Sanghani S; Schiel MA; Yu M; Burns M; Tong Y; Hinkle DT; Coleman N; Robb B; LeBlanc J; Clark R; Bufill J; Curie C; Loehrer PJ; Cardenes H
Cancer Chemother Pharmacol; 2012 Jul; 70(1):25-32. PubMed ID: 22610353
[TBL] [Abstract][Full Text] [Related]
22. Preoperative Volumetric Modulated Arc Therapy With Simultaneous Integrated Boost for Locally Advanced Distal Rectal Cancer.
Yang Y; Liu Q; Jia B; Du X; Dai G; Liu H; Chen J; Zeng M; Wen K; Zhu Y; Wang Y; Feng L
Technol Cancer Res Treat; 2019 Jan; 18():1533033818824367. PubMed ID: 30803368
[TBL] [Abstract][Full Text] [Related]
23. Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer.
Crane CH; Eng C; Feig BW; Das P; Skibber JM; Chang GJ; Wolff RA; Krishnan S; Hamilton S; Janjan NA; Maru DM; Ellis LM; Rodriguez-Bigas MA
Int J Radiat Oncol Biol Phys; 2010 Mar; 76(3):824-30. PubMed ID: 19464823
[TBL] [Abstract][Full Text] [Related]
24. Neoadjuvant Chemotherapy with Capecitabine, Oxaliplatin and Bevacizumab Followed by Concomitant Chemoradiation and Surgical Resection in Locally Advanced Rectal Cancer with High Risk of Recurrence - A Phase II Study.
Eisterer W; Piringer G; DE Vries A; Öfner D; Greil R; Tschmelitsch J; Samonigg H; Sölkner L; Gnant M; Thaler J;
Anticancer Res; 2017 May; 37(5):2683-2691. PubMed ID: 28476845
[TBL] [Abstract][Full Text] [Related]
25. Phase I trial of cetuximab in combination with capecitabine, weekly irinotecan, and radiotherapy as neoadjuvant therapy for rectal cancer.
Hofheinz RD; Horisberger K; Woernle C; Wenz F; Kraus-Tiefenbacher U; Kähler G; Dinter D; Grobholz R; Heeger S; Post S; Hochhaus A; Willeke F
Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1384-90. PubMed ID: 16979839
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of neoadjuvant intensity-modulated radiotherapy with concurrent capecitabine for locally advanced rectal cancer.
Wang L; Li ZY; Li ZW; Li YH; Sun YS; Ji JF; Gu J; Cai Y
Dis Colon Rectum; 2015 Feb; 58(2):186-92. PubMed ID: 25585076
[TBL] [Abstract][Full Text] [Related]
27. Phase I trial of neoadjuvant chemoradiotherapy (CRT) with capecitabine and weekly irinotecan followed by laparoscopic total mesorectal excision (LTME) in rectal cancer patients.
Ugidos L; Delgado S; Conill C; Ginés A; Gallego R; Ayuso JR; Miquel R; Tosca M; de Lacy A; Castells A; Maurel J
Invest New Drugs; 2009 Jun; 27(3):262-8. PubMed ID: 18923810
[TBL] [Abstract][Full Text] [Related]
28. Bevacizumab, capecitabine, amifostine, and preoperative hypofractionated accelerated radiotherapy (HypoArc) for rectal cancer: a Phase II study.
Koukourakis MI; Giatromanolaki A; Tsoutsou P; Lyratzopoulos N; Pitiakoudis M; Kouklakis G; Chloropoulou PA; Manolas K; Sivridis E
Int J Radiat Oncol Biol Phys; 2011 Jun; 80(2):492-8. PubMed ID: 20584585
[TBL] [Abstract][Full Text] [Related]
29. A phase I trial of preoperative radiotherapy and capecitabine for locally advanced, potentially resectable rectal cancer.
Ngan SY; Michael M; Mackay J; McKendrick J; Leong T; Lim Joon D; Zalcberg JR
Br J Cancer; 2004 Sep; 91(6):1019-24. PubMed ID: 15305186
[TBL] [Abstract][Full Text] [Related]
30. Neoadjuvant chronomodulated capecitabine with radiotherapy in rectal cancer: a phase II brunch regimen study.
Akgun Z; Saglam S; Yucel S; Gural Z; Balik E; Cipe G; Yildiz S; Kilickap S; Okyar A; Kaytan-Saglam E
Cancer Chemother Pharmacol; 2014 Oct; 74(4):751-6. PubMed ID: 25102935
[TBL] [Abstract][Full Text] [Related]
31. A phase II study of neoadjuvant bevacizumab plus capecitabine and concomitant radiotherapy in patients with locally advanced rectal cancer.
Gasparini G; Torino F; Ueno T; Cascinu S; Troiani T; Ballestrero A; Berardi R; Shishido J; Yoshizawa A; Mori Y; Nagayama S; Morosini P; Toi M
Angiogenesis; 2012 Mar; 15(1):141-50. PubMed ID: 22212406
[TBL] [Abstract][Full Text] [Related]
32. Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: Phase I trial results.
Czito BG; Bendell JC; Willett CG; Morse MA; Blobe GC; Tyler DS; Thomas J; Ludwig KA; Mantyh CR; Ashton J; Yu D; Hurwitz HI
Int J Radiat Oncol Biol Phys; 2007 Jun; 68(2):472-8. PubMed ID: 17498568
[TBL] [Abstract][Full Text] [Related]
33. Preoperative chemoradiation with cetuximab, irinotecan, and capecitabine in patients with locally advanced resectable rectal cancer: a multicenter Phase II study.
Kim SY; Hong YS; Kim DY; Kim TW; Kim JH; Im SA; Lee KS; Yun T; Jeong SY; Choi HS; Lim SB; Chang HJ; Jung KH
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):677-83. PubMed ID: 20888703
[TBL] [Abstract][Full Text] [Related]
34. A phase II study of cetuximab, capecitabine and radiotherapy in neoadjuvant treatment of patients with locally advanced resectable rectal cancer.
Velenik V; Ocvirk J; Oblak I; Anderluh F
Eur J Surg Oncol; 2010 Mar; 36(3):244-50. PubMed ID: 20042310
[TBL] [Abstract][Full Text] [Related]
35. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial.
Hofheinz RD; Wenz F; Post S; Matzdorff A; Laechelt S; Hartmann JT; Müller L; Link H; Moehler M; Kettner E; Fritz E; Hieber U; Lindemann HW; Grunewald M; Kremers S; Constantin C; Hipp M; Hartung G; Gencer D; Kienle P; Burkholder I; Hochhaus A
Lancet Oncol; 2012 Jun; 13(6):579-88. PubMed ID: 22503032
[TBL] [Abstract][Full Text] [Related]
36. Phase I study of postoperative radiotherapy combined with capecitabine for gastric cancer.
Wang X; Jin J; Li YX; Ren H; Fang H; Wang SL; Liu YP; Wang WH; Yu ZH; Song YW; Liu XF
World J Gastroenterol; 2014 Jan; 20(4):1067-73. PubMed ID: 24574780
[TBL] [Abstract][Full Text] [Related]
37. Neoadjuvant capecitabine combined with standard radiotherapy in patients with locally advanced rectal cancer: mature results of a phase II trial.
Dunst J; Debus J; Rudat V; Wulf J; Budach W; Hoelscher T; Reese T; Mose S; Roedel C; Zuehlke H; Hinke A
Strahlenther Onkol; 2008 Sep; 184(9):450-6. PubMed ID: 19016023
[TBL] [Abstract][Full Text] [Related]
38. [Influence of preoperative chemoradiotherapy on changes of epidermal growth factor receptor expression in patients treated by preoperative chemoradiotherapy for local advanced rectal carcinoma].
Richter I; Dvořák J; Blüml A; Cermáková E; Bartoš J; Urbanec M; Sitorová V; Ryška A; Sirák I; Buka D; Ferko A; Melichar B; Petera J
Klin Onkol; 2014; 27(5):361-6. PubMed ID: 25312714
[TBL] [Abstract][Full Text] [Related]
39. Four-week neoadjuvant intensity-modulated radiation therapy with concurrent capecitabine and oxaliplatin in locally advanced rectal cancer patients: a validation phase II trial.
Arbea L; Martínez-Monge R; Díaz-González JA; Moreno M; Rodríguez J; Hernández JL; Sola JJ; Ramos LI; Subtil JC; Nuñez J; Chopitea A; Cambeiro M; Gaztañaga M; García-Foncillas J; Aristu J
Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):587-93. PubMed ID: 22079731
[TBL] [Abstract][Full Text] [Related]
40. A phase II study of capecitabine and irinotecan in combination with concurrent pelvic radiotherapy (CapIri-RT) as neoadjuvant treatment of locally advanced rectal cancer.
Willeke F; Horisberger K; Kraus-Tiefenbacher U; Wenz F; Leitner A; Hochhaus A; Grobholz R; Willer A; Kähler G; Post S; Hofheinz RD
Br J Cancer; 2007 Mar; 96(6):912-7. PubMed ID: 17325705
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
